@article{article_254553, title={Long term survival in a patient with recurrent metastatic Ewing sarcoma treated with irinotecan and temozolomide}, journal={Cukurova Medical Journal}, volume={41}, pages={811–814}, year={2016}, DOI={10.17826/cutf.254553}, author={Gelincik, Hakan and Küpeli, Serhan}, keywords={Ewing sarkom,irinotekan,temozolomid}, abstract={<p>Ewing sarcoma family of tumor is the second most common bone tumor in children and young adults, after osteosarcoma. Different chemotherapeutic regimens are used in treatment of relapsed/recurrent Ewing sarcoma. Promising results were achieved with combination of irinotecan and temozolomide. Our case was a 13-year-old female with relapsed Ewing sarcoma and after 12 cycles of irinotecan (20 mg/m2/10 days) and temozolomide (100mg/m2/5 days) treatment she had not any complaints, and her radiological lesions remained stable for 66 months. Irinotecan and temozolomide have been used successfully in treatment of relapsed/recurrent Ewing sarcoma, but there is a need for randomized prospective studies with larger patient groups for establishing the efficacy of this treatment protocol. <br /> </p>}, number={4}, publisher={Çukurova Üniversitesi}